Express treatment of pancreatic cancer, Amgen KRAS inhibitor achieves 84% ​​disease control rate

▎WuXi AppTec Content Team Editor A few days ago, Amgen announced the latest efficacy and safety results of its KRAS G12C inhibitor, Lumarkras (sotorasib), in the treatment of patients with advanced pancreatic cancer harboring KRAS G12C mutations
.

The data showed that Lumarkras demonstrated clinically meaningful anticancer activity and a positive benefit/risk ratio
.

Pancreatic cancer is a very lethal malignant tumor
.

The press release notes that patients with disease progression after first-line therapy still have a high unmet need, and current FDA-approved second-line therapies only provide about 6 months of survival and a 16% response rate
.

There is currently no therapy that provides a survival benefit in patients with disease progression after first- and second-line chemotherapy
.

It is estimated that about 90% of pancreatic cancer patients carry KRAS gene mutations, of which KRAS G12C accounts for 1-2%
.

Lumarkras is a covalent inhibitor of KRAS G12C developed by Amgen
.

It irreversibly inhibits KRAS activity by binding to the KRAS G12C mutant, locking KRAS in an inactive state
.

In May last year, it received accelerated approval from the U.
S.
Food and Drug Administration for the treatment of patients with non-small cell lung cancer carrying the KRAS G12C mutation
.

It also exhibits anticancer activity in the treatment of colorectal cancer
.

The latest data show that Lumakras achieved an objective response rate of 21% and a disease control rate of 84% in 38 patients with advanced pancreatic cancer who had undergone multiple prior treatments
.

Nearly 80% of treated patients had already received two or more prior treatments
.

At a median follow-up of 16.
8 months, the median duration of response was 5.
7 months
.

The median progression-free survival was 4 months, and the median overall survival was nearly 7 months
.

"Based on these exciting data, we will expand the clinical trial to enroll more patients with pancreatic and other cancer types to better understand the efficacy and safety of Lumakras beyond non-small cell lung cancer and colorectal cancer
.

said Dr.
David M.
Reese, executive vice president of research and development at Amgen
.

Reference: [1] LUMAKRAS® (SOTORASIB) SHOWS ENCOURAGING AND CLINICALLY MEANINGFUL ANTICANCER ACTIVITY IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED PANCREATIC CANCER IN CODEBREAK 100 TRIAL.
Retrieved February 15, 2022, from https:// newsroom/press-releases/2022/02/lumakras-sotorasib-shows-encouraging-and-clinically-meaningful-anticancer-activity-in-patients-with-kras-g12cmutated-advanced-pancreatic-cancer-in-codebreak-100- trial disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.

This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.

This article is also not a treatment plan recommendation
.

For guidance on treatment options, please visit a regular hospital
.